ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 4552.0 | 3740.2 | 4001.0 |
| Other income | 134.2 | 152.8 | 103.7 |
| Total income | 4686.2 | 3892.9 | 4104.7 |
| Profit before exceptional items & tax | 964.6 | 772.0 | 895.8 |
| Exceptional items | 35.0 | 0.0 | 0.0 |
| Profit before tax | 999.6 | 772.0 | 895.8 |
| Net profit | 667.1 | 521.0 | 779.1 |
| Operating margin | 21.3% | 19.8% | 21.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -14.40% |
|---|---|
| Net profit, quarter on quarter | +28.00% |
| Revenue, year on year | +13.80% |
| Operating profit, year on year | +4.80% |
| Operating profit, quarter on quarter | +34.10% |
BSE results filing, NSE: ALKEM. Figures extracted from the filing.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,218.00
- Market cap
- ₹62,389 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 28.9×Sector 43.8×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Results Update
Alkem posted Q2FY27 revenue of ₹4,552 Cr, up 14% YoY, with 22.5% EBITDA margin. Net profit fell 11.7% to ₹675 Cr on higher R&D.
Alkem Laboratories Management Change
Alkem Laboratories appointed Mr. Gopal Kothari as CFO and Key Managerial Personnel effective 2 December 2026. The 24-year finance veteran is a CA and CS.
Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
Alkem Laboratories Board Meeting Date
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.
Alkem Laboratories Management Change
Alkem Laboratories appointed Dr. Amrut Naik as CEO effective November 11, 2026. The Board designated him as Key Managerial Personnel at its November 3 meeting.
Alkem Laboratories Business Update
Alkem informed the exchange that US FDA completed inspection of its Mandva API facility with no Form 483 observations. The clean result confirms regulatory compliance.